Doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide for osteosarcoma

Hospital Pharmacy

Volumn 42, Issue 9, 2007, Pages 801-815

  Mbue, John E ^a   Solimando Jr , Dominic A ^a,b   Waddell, J Aubrey ^a,c,d  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c The University of Tennessee Extension   (United States)

^d BLOUNT MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; BICARBONATE; CISPLATIN; COLONY STIMULATING FACTOR; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; DIURETIC AGENT; DOLASETRON MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANISETRON; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PALONOSETRON; PROCHLORPERAZINE; PROMETHAZINE; SEROTONIN ANTAGONIST; STEROID;

ADJUVANT THERAPY; ANEMIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG URINE LEVEL; ERYTHEMA; EXTRAVASATION; FEBRILE NEUTROPENIA; HUMAN; HYDRATION; HYPERSENSITIVITY REACTION; HYPOPHOSPHATEMIA; INFECTION; KIDNEY DISEASE; KIDNEY INJURY; LABORATORY TEST; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; OTOTOXICITY; PERICARDIAL EFFUSION; PRURITUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; URINE VOLUME; URTICARIA; VOMITING;

EID: 34848917334     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4209-801     Document Type: Review

References (37)

1. Winkler K, Bielack SS, Delling G, et al. Effects of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer. 1990;66:1703-1710.
2. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893-899.
3. Daw NC, Billups CA, Rodriguez-Galindo C, et al. Metastatic osteosarcoma. Cancer. 2006;106:403-412.
4. Bacci G, Mercuri M, Briccoli A, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation: results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer. 1997;79:245-254.
5. Harris M, Gieser P, Goorin A, et al. Treatment of metastatic osteosarcoma at diagnosis: a pediatric oncology group study. J Clin Oncol. 1998;16(11):3641-3648.
6. Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experiences at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose methotrexate and ifosfamide. Ann Oncol. 2003;14:1126-1134.
7. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845-8852.
8. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cis-platin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
9. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72:3227-3238.
10. Rha SY, Chung HC, Gong SJ, et al. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma. Oncology Rep. 1999;6:631-637.
11. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the instituto ortopedico rizzoli according to the instituto ortopedico/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18(24):4016-4027.
12. Patel SJ, Lynch JW Jr, Johnson T, et al. Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol. 2002;25(5):489-495.
13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology-Bone Cancer. V.1.2007. http://www.nccn.org/professionals/ physician_gls/PDF/bone.pdf. Accessed July 25, 2007.
14. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-109.
15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines - Antiemesis. V.1.2007. http://www.nccn.org/professionals/physi cian_gls/PDF/antiemesis.pdf. Accessed July 25, 2007.
16. Kris MG, Hesketh PJ, Somerfield MR, et al. American society of clinical oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932-2947.
17. Multinational Association for Supportive Care in Cancer. Antiemetic Guidelines. 2007. http://www.mascc.org/ media/Resource_centers/MASCC_ Guidelines_Update.pdf. Accessed July 25, 2007.
18. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985; 3:1379-1384.
19. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6):1289-1294.
20. Terrey JP, Aapro MS. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res. 1996;8:281-288.
21. Carmichael J, Keizer HJ, Cupissol D, Milliez J, Scheidel P, Schindler AE. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998;9(5):381-385.
22. de Wit R, de Boer AC, vd Linden GH, Stoter G, Sparreboom A, Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001;19;85(8):1099-1101.
23. Smith IE. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol. 1993;119(6):350-354.
24. Soukop M. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer. 1994;2(3):177-183.
25. Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993;50(2):147-158.
26. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001;24(1):19-38.
27. Pitman SW, Frei E 3rd. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep. 1977;61:695-701.
28. Weiss RB. Hypersensitivity reactions. Semin Oncol. 1992;19(5):458-477.
29. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-3205.
30. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Myeloid Growth Factors. V.1.2006. http:// www.nccn.org/ professionals/physician_gls/PDF/myeloid_growth.pdf. Accessed July 25, 2007.
31. Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer. 1982;49(9):1796-1799.
32. Larson DL. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surgery. 1985;75(3):397-405.
33. Mullin S, Beckwith MC, Tyler LS. Prevention and management of antineoplastic extravasation injury. Hosp Pharm. 2000;35(1):57-74.
34. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21(1):33-64.
35. Aronoff GR, Berns JS, Brier ME, et al. Drug Prescribing in Renal Failure. 4,h ed. Philadelphia: American College of Physicians; 1999:74.
36. Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol. 2006;33:50-67.
37. Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer. 1998;34:33-46.